Drug Patents owned by Noven
1. List of Minivelle drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9724310 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(5 years from now) | |
| US8231906 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9730900 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(5 years from now) | |
| US9833419 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(5 years from now) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 October, 2012
Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent no. 9730900
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
How can I launch a generic of MINIVELLE before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic